SELLAS Q2 2026 net loss $9.6M; GPS Phase 3 nears 80th-event final analysis

SELLAS Life Sciences Group, Inc.

2026-Q2 EPS reported -$0.10

Q2 2026 net loss $9.6M ($0.05/sh) vs $6.6M ($0.07/sh) in Q2 2025; H1 loss $18.0M.
R&D expense $6.3M in Q2 2026 (vs $3.9M) on BLA prep for GPS; G&A $4.4M (vs $3.0M).
Cash and equivalents $138.3M as of June 30, 2026.
Phase 3 REGAL (GPS) in AML will conduct final analysis after pre-specified 80th event; timing unannounced.
28 patients enrolled in Phase 2 SLS009 frontline AML; topline data expected Q4 2026; preclinical PDAC data upcoming.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.